Atara Biotherapeutics (NASDAQ:ATRA – Get Free Report) was upgraded by stock analysts at Freedom Capital from a “strong sell” rating to a “hold” rating in a research note issued to investors on Monday,Zacks.com reports.
Other research analysts have also recently issued research reports about the company. Canaccord Genuity Group set a $13.00 target price on Atara Biotherapeutics and gave the company a “buy” rating in a research note on Friday, May 8th. Wall Street Zen raised Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Atara Biotherapeutics in a research note on Friday, March 27th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $9.50.
Read Our Latest Stock Report on Atara Biotherapeutics
Atara Biotherapeutics Stock Down 4.5%
Atara Biotherapeutics (NASDAQ:ATRA – Get Free Report) last released its earnings results on Tuesday, May 12th. The biotechnology company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.04. The business had revenue of $0.52 million for the quarter, compared to analysts’ expectations of $2.90 million. Atara Biotherapeutics had a negative return on equity of 79.12% and a negative net margin of 40.91%. As a group, equities analysts anticipate that Atara Biotherapeutics will post 0.2 earnings per share for the current year.
Insider Transactions at Atara Biotherapeutics
In other Atara Biotherapeutics news, major shareholder Innovation Ltd Panacea sold 313,446 shares of the company’s stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $10.10, for a total transaction of $3,165,804.60. Following the completion of the sale, the insider directly owned 1,011,000 shares in the company, valued at $10,211,100. This represents a 23.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 41.20% of the stock is currently owned by insiders.
Institutional Trading of Atara Biotherapeutics
Several institutional investors have recently added to or reduced their stakes in ATRA. Raymond James Financial Inc. purchased a new stake in Atara Biotherapeutics during the second quarter valued at about $31,000. Dimensional Fund Advisors LP purchased a new stake in Atara Biotherapeutics during the fourth quarter valued at about $181,000. Walleye Capital LLC purchased a new stake in Atara Biotherapeutics during the fourth quarter valued at about $220,000. Marshall Wace LLP purchased a new stake in Atara Biotherapeutics during the second quarter valued at about $327,000. Finally, Quadrature Capital Ltd boosted its position in Atara Biotherapeutics by 22.8% during the fourth quarter. Quadrature Capital Ltd now owns 20,321 shares of the biotechnology company’s stock valued at $368,000 after buying an additional 3,779 shares during the period. 70.90% of the stock is currently owned by hedge funds and other institutional investors.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc is a biotechnology company focused on the discovery, development and commercialization of novel T-cell immunotherapies to transform the treatment of cancer and autoimmune disease. Headquartered in South San Francisco, California, Atara leverages its proprietary off-the-shelf allogeneic Epstein-Barr virus (EBV)-directed T-cell platform to generate engineered cell therapies designed to target EBV-driven malignancies and immune-mediated disorders.
The company’s lead product candidate, tabelecleucel, is an off-the-shelf, EBV-specific T-cell therapy in clinical development for the treatment of EBV-positive post-transplant lymphoproliferative disease (PTLD) and other EBV-associated cancers.
Featured Stories
- Five stocks we like better than Atara Biotherapeutics
- Why Applied Optoelectronics Stock May Be Near a Turning Point
- From High-Yield to High-Growth: 3 Stocks Boosting Dividends
- Is Everspin Technologies the Next AI Edge Breakout?
- 5 Robotics Stocks to Watch as Physical AI Builds Momentum
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
